PolyPid Ltd. (NASDAQ:PYPD) Receives Average Recommendation of “Moderate Buy” from Brokerages

PolyPid Ltd. (NASDAQ:PYPD) has been given an average rating of “Moderate Buy” by the five ratings firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $11.3333.

PYPD has been the subject of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $13.00 price objective on shares of PolyPid in a report on Tuesday, July 21st. Craig Hallum set a $12.00 price target on shares of PolyPid in a report on Wednesday, July 22nd. Finally, Weiss Ratings raised shares of PolyPid from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 23rd.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. AIGH Capital Management LLC increased its holdings in shares of PolyPid by 26.1% in the fourth quarter. AIGH Capital Management LLC now owns 1,342,972 shares of the company’s stock worth $5,828,000 after purchasing an additional 277,844 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of PolyPid during the 4th quarter worth approximately $66,000. ADAR1 Capital Management LLC bought a new position in shares of PolyPid during the 4th quarter valued at approximately $451,000. XTX Topco Ltd grew its holdings in shares of PolyPid by 50.0% in the fourth quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock valued at $142,000 after purchasing an additional 10,888 shares in the last quarter. Finally, HighTower Advisors LLC purchased a new position in shares of PolyPid in the fourth quarter valued at $44,000. 26.47% of the stock is owned by hedge funds and other institutional investors.

PolyPid Trading Down 5.8%

Shares of NASDAQ PYPD opened at $3.75 on Wednesday. PolyPid has a 12 month low of $3.06 and a 12 month high of $5.73. The firm has a market capitalization of $71.55 million, a PE ratio of -1.96 and a beta of 1.40. The firm has a fifty day simple moving average of $4.80 and a two-hundred day simple moving average of $4.57.

PolyPid (NASDAQ:PYPD) last released its earnings results on Wednesday, May 13th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.12. On average, sell-side analysts predict that PolyPid will post -1.63 earnings per share for the current year.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.